<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35264450</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1468-330X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>93</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neurology, neurosurgery, and psychiatry</Title>
          <ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Comparative whole transcriptome analysis of Parkinson's disease focusing on the efficacy of zonisamide.</ArticleTitle>
        <Pagination>
          <StartPage>509</StartPage>
          <EndPage>512</EndPage>
          <MedlinePgn>509-512</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2021-328742</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE">Interindividual variations in responsiveness to zonisamide in patients with Parkinson's disease (PD) have been observed in clinical settings. To decipher the molecular mechanisms determining the efficacy of zonisamide, we conducted whole transcriptome sequencing analysis of patients with PD.</AbstractText>
          <AbstractText Label="METHODS">We selected 23 super-responders (SRs) and 25 non-responders (NRs) to zonisamide from patients with PD who had participated in a previous clinical trial for the approval of zonisamide for the treatment of 'wearing-off'. Whole transcriptome analysis of peripheral blood was conducted on samples taken before and 12 weeks after zonisamide treatment. We performed differential gene expression analysis to compare between the SRs and NRs at each time point.</AbstractText>
          <AbstractText Label="RESULTS">Differentially expressed genes in the pre-treatment samples were significantly enriched for glutamatergic synapses and insulin-like growth factor binding (<i>P</i> <sub>adj</sub>=7.8 × 10<sup>-3</sup> and 0.029, respectively). The gene sets associated with these functions changed more dynamically by treatment in SRs than NRs (p=7.2 × 10<sup>-3</sup> and 8.2 × 10<sup>-3</sup>, respectively).</AbstractText>
          <AbstractText Label="CONCLUSIONS">Our results suggest that the efficacy of zonisamide in PD patients is associated with glutamate-related synaptic modulation and p53-mediated dopaminergic neural loss. Their transcriptomic differences could be captured before treatment, which would lead to the realisation of future personalised treatment.</AbstractText>
          <CopyrightInformation>© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Naito</LastName>
            <ForeName>Tatsuhiko</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-2779-4600</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Satake</LastName>
            <ForeName>Wataru</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan satake@m.u-tokyo.ac.jp toda@m.u-tokyo.ac.jp.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cha</LastName>
            <ForeName>Pei-Chieng</ForeName>
            <Initials>PC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Genomic Medicine, Research Institute, National Cerebral and Cardiovascular Center, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kobayashi</LastName>
            <ForeName>Kazuhiro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murata</LastName>
            <ForeName>Miho</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, NCNP Hospital, Kodaira, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Toda</LastName>
            <ForeName>Tatsushi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan satake@m.u-tokyo.ac.jp toda@m.u-tokyo.ac.jp.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA>
        <NlmUniqueID>2985191R</NlmUniqueID>
        <ISSNLinking>0022-3050</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>459384H98V</RegistryNumber>
          <NameOfSubstance UI="D000078305">Zonisamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078305" MajorTopicYN="N">Zonisamide</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Neurogenetics</Keyword>
        <Keyword MajorTopicYN="Y">parkinson's disease</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>5</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35264450</ArticleId>
        <ArticleId IdType="pmc">PMC9016247</ArticleId>
        <ArticleId IdType="doi">10.1136/jnnp-2021-328742</ArticleId>
        <ArticleId IdType="pii">jnnp-2021-328742</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Murata M, Hasegawa K, Kanazawa I, et al. . Zonisamide improves wearing-off in Parkinson’s disease: A randomized, double-blind study. Mov Disord
2015;30:1343–50. 10.1002/mds.26286
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.26286</ArticleId>
            <ArticleId IdType="pubmed">26094993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cha P-C, Satake W, Ando-Kanagawa Y, et al. . Genome-wide association study identifies zonisamide responsive gene in Parkinson's disease patients. J Hum Genet
2020;65:693–704. 10.1038/s10038-020-0760-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s10038-020-0760-8</ArticleId>
            <ArticleId IdType="pmc">PMC8075945</ArticleId>
            <ArticleId IdType="pubmed">32355309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dobin A, Davis CA, Schlesinger F, et al. . Star: ultrafast universal RNA-seq aligner. Bioinformatics
2013;29:15–21. 10.1093/bioinformatics/bts635
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId>
            <ArticleId IdType="pmc">PMC3530905</ArticleId>
            <ArticleId IdType="pubmed">23104886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics
2011;12:323. 10.1186/1471-2105-12-323
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2105-12-323</ArticleId>
            <ArticleId IdType="pmc">PMC3163565</ArticleId>
            <ArticleId IdType="pubmed">21816040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol
2014;15:1–21. 10.1186/s13059-014-0550-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ashburner M, Ball CA, Blake JA, et al. . Gene ontology: tool for the unification of biology. Nat Genet
2000;25:25–9. 10.1038/75556
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/75556</ArticleId>
            <ArticleId IdType="pmc">PMC3037419</ArticleId>
            <ArticleId IdType="pubmed">10802651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kanehisa M, Goto S. Kegg: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res
2000;28:27–30. 10.1093/nar/28.1.27
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/28.1.27</ArticleId>
            <ArticleId IdType="pmc">PMC102409</ArticleId>
            <ArticleId IdType="pubmed">10592173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Reimand J, Kull M, Peterson H, et al. . G:Profiler—a web-based toolset for functional profiling of gene lists from large-scale experiments. Nucleic Acids Res
2007;35:193–200. 10.1093/nar/gkm226
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkm226</ArticleId>
            <ArticleId IdType="pmc">PMC1802568</ArticleId>
            <ArticleId IdType="pubmed">17158163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fukuyama K, Tanahashi S, Hoshikawa M, et al. . Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway. Neuropharmacology
2014;76 Pt A:137–45. 10.1016/j.neuropharm.2013.08.002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2013.08.002</ArticleId>
            <ArticleId IdType="pubmed">23973311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li C, Xue L, Liu Y, et al. . Zonisamide for the treatment of Parkinson disease: a current update. Front Neurosci
2020;14:1–12. 10.3389/fnins.2020.574652
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2020.574652</ArticleId>
            <ArticleId IdType="pmc">PMC6989613</ArticleId>
            <ArticleId IdType="pubmed">32038151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lu T, Kim P, Luo Y. Tp53 gene mediates distinct dopaminergic neuronal damage in different dopaminergic neurotoxicant models. Neural Regen Res
2017;12:1413–7. 10.4103/1673-5374.215243
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/1673-5374.215243</ArticleId>
            <ArticleId IdType="pmc">PMC5649453</ArticleId>
            <ArticleId IdType="pubmed">29089978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Morrison RS, Kinoshita Y. The role of p53 in neuronal cell death. Cell Death Differ
2000;7:868–79. 10.1038/sj.cdd.4400741
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cdd.4400741</ArticleId>
            <ArticleId IdType="pubmed">11279532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kawajiri S, Machida Y, Saiki S, et al. . Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD. Neurosci Lett
2010;481:88–91. 10.1016/j.neulet.2010.06.058
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neulet.2010.06.058</ArticleId>
            <ArticleId IdType="pubmed">20600601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Levine AJ, Feng Z, Mak TW, et al. . Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev
2006;20:267–75. 10.1101/gad.1363206
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1363206</ArticleId>
            <ArticleId IdType="pubmed">16452501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tan E-K, Chao Y-X, West A, et al. . Parkinson disease and the immune system - associations, mechanisms and therapeutics. Nat Rev Neurol
2020;16:303–18. 10.1038/s41582-020-0344-4
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-020-0344-4</ArticleId>
            <ArticleId IdType="pubmed">32332985</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
